Clinical Trial Update: ACP-104 in Acutely Psychotic Subjects With Schizophrenia [Phase 2]

View source ↗

Summary

Phase 2 trial update of ACP-104 in acutely psychotic subjects with schizophrenia; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• ACP-104

Snippet

Sponsor: ACADIA Pharmaceuticals Inc. | Conditions: Schizophrenia | Phase 2 | Status: COMPLETED